Linked Life Data

7654489

Source:http://linkedlifedata.com/resource/pubmed/id/7654489

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
6
pubmed:dateCreated
1995-9-29
pubmed:abstractText
The pharmacokinetics of dexfenfluramine (d-F) and its metabolite dexnorfenfluramine (d-NF) were compared in 10 obese (145 +/- 13 s.d. % of ideal body weight (IBW)) and 10 non-obese healthy volunteers (93 +/- 8% IBW). Each group included five men and five women, aged 28 +/- 8 years. Subjects were given single doses of d-F i.v. (15.5 mg base infused over 3 h) and orally (25.9 mg base in capsules) on separate occasions. After i.v. infusion in obese subjects, the volume of distribution (Vss) of d-F was significantly higher (969.7 +/- 393.3 l; 95% CI 688.6-1250 l) than in controls (668.7 +/- 139.6 l; 95% CI 568.9-768.5 l; P < 0.01). Clearance was not significantly different (43.9 +/- 21.0 l h-1 vs 37.3 +/- 10.6 l h-1) and the terminal half-life tended to be longer (17.8 +/- 9.4 vs 13.5 +/- 3.9 h NS). Combined data from the two groups indicated a positive correlation between Vss and % IBW (r = 0.544; P < 0.02). The oral bioavailability of d-F was 0.61 +/- 0.15 in obese subjects and 0.69 +/- 0.11 in controls. There was no significant difference between obese subjects and controls in Cmax, tmax and t1/2,z (Cmax: 20.1 +/- 6.7 and 27.3 +/- 6.2 micrograms l-1; tmax: 3.5 vs 3.0; t1/2,z: 16.5 +/- 7.1 vs 14.5 +/- 2.6 h respectively). The AUC ratio expressed in molar units for d-F/d-NF was 2.29 +/- 1.78 (i.v.) vs 1.25 +/- 0.64 (oral) in obese subjects and 2.05 +/- 1.26 (i.v.) vs 1.40 +/- 0.87 (oral) in controls.(ABSTRACT TRUNCATED AT 250 WORDS)
pubmed:commentsCorrections
http://linkedlifedata.com/resource/pubmed/commentcorrection/7654489-1379149, http://linkedlifedata.com/resource/pubmed/commentcorrection/7654489-2750211, http://linkedlifedata.com/resource/pubmed/commentcorrection/7654489-3052814, http://linkedlifedata.com/resource/pubmed/commentcorrection/7654489-3524955, http://linkedlifedata.com/resource/pubmed/commentcorrection/7654489-4076322, http://linkedlifedata.com/resource/pubmed/commentcorrection/7654489-4401963, http://linkedlifedata.com/resource/pubmed/commentcorrection/7654489-5430408, http://linkedlifedata.com/resource/pubmed/commentcorrection/7654489-6546907, http://linkedlifedata.com/resource/pubmed/commentcorrection/7654489-7138139, http://linkedlifedata.com/resource/pubmed/commentcorrection/7654489-7160955, http://linkedlifedata.com/resource/pubmed/commentcorrection/7654489-8403734
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jun
pubmed:issn
0306-5251
pubmed:author
pubmed:issnType
Print
pubmed:volume
39
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
684-7
pubmed:dateRevised
2009-11-18
pubmed:meshHeading
pubmed:year
1995
pubmed:articleTitle
The pharmacokinetics of dexfenfluramine in obese and non-obese subjects.
pubmed:affiliation
Service de Pharmacologie, Hôpital Saint-Antoine, Paris, France.
pubmed:publicationType
Journal Article, Clinical Trial, Randomized Controlled Trial